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Abstract
The impact of ﬂuoroquinolone resistance of Campylobacter jejuni and Campylobacter coli isolates on the outcome of the disease in spo-
radic Campylobacter infections of Finnish individuals was studied. Questionnaires were sent, during a 6-month study period, to patients
who were stool culture-positive for Campylobacter spp. In total, 192 returned questionnaires were analysed and assessed, together with
the susceptibility data of the respective bacterial isolates. Only one (2%) of the domestic, but half of the imported, Campylobacter iso-
lates were resistant to ciproﬂoxacin. Ciproﬂoxacin resistance was not associated with particularly severe infection. Instead, ciproﬂoxa-
cin-susceptible Campylobacter isolates, as compared to ciproﬂoxacin-resistant isolates, showed a tendency to cause more severe
infections, characterized by bloody stools and hospitalization.
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Introduction
Campylobacter jejuni and Campylobacter coli cause bacterial
enteritis worldwide [1]. In Finland, most of the Campylobacter
cases are imported, and domestically acquired infections
occur mainly during the seasonal peak in the summer [2].
Eating improperly cooked meat, especially chicken, is a com-
monly recognized risk factor for the infection [1]. Recently,
associations were shown between campylobacteriosis in
the peak season and drinking water from a dug well and
swimming in natural sources of water [3]. Typical symp-
toms of Campylobacter infection include diarrhoea, sometimes
with blood, in addition to fever, abdominal pain, nausea, and
myalgia [4]. Bloody diarrhoea and vomiting are associated
with a longer and more severe clinical course of the infec-
tion [5].
The need for antimicrobial treatment of Campylobacter
infections has been discussed, and a recent meta-analysis
including 11 randomized clinical trials indicated that early
antimicrobial treatment shortens the duration of diarrhoea,
although only marginally [6]. However, increased resistance
of Campylobacter isolates to antimicrobial agents is alarming.
In particular, resistance to ciproﬂoxacin has substantially
increased since the early 1990s [7–10]. It is highly probable
that the use of antimicrobial agents in veterinary medicine is
mainly responsible for the decreasing susceptibility of Cam-
pylobacter to antimicrobials [9]. Whether ﬂuoroquinolone-
resistant Campylobacter isolates cause more severe infections
than the susceptible ones has been debated, but the results
have so far been contradictory [11–16]. The present aim
was to study the possible impact of ciproﬂoxacin resistance
of C. jejuni and C. coli isolates on the outcome of the disease
in sporadic Campylobacter infections in Finnish individuals.
Materials and Methods
Stool samples of patients were studied for Campylobacter,
Salmonella, Shigella and Yersinia enterocolitica using routine
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culture methods at the Helsinki University Central Hospital
Laboratory, the central clinical microbiology laboratory of
the Helsinki metropolitan and surrounding areas. Stool cul-
tures were taken according to routine clinical procedures.
From 1 July to 31 December 2006, Campylobacter stool cul-
ture isolates from sporadic cases were collected and stored
for further analysis. In order to obtain information concern-
ing the clinical course of the infection, the patients’ physi-
cians who had referred samples for laboratory testing or
coordinated the treatment were contacted by mail, and
asked to forward the information about the study along with
a questionnaire to the patient. Each patient with a stool cul-
ture positive for C. jejuni or C. coli was to receive a question-
naire including questions on general health condition,
previously taken antimicrobial and antidiarrhoeal drugs, travel
within 2 weeks preceding the illness, and the clinical course
and possible antimicrobial treatment of the illness. The
patients were asked to return the questionnaire in a pre-paid
envelope to the investigators. The questionnaire and the
respective bacterial isolate were linked by a referral number.
Data obtained in response to speciﬁc questions in the
questionnaire were included in the analyses only when the
respective questions had been adequately answered. All data
concerning symptoms, medication and travel were obtained
from the questionnaires. The study was approved by the Ethics
Committee of the Hospital District of Helsinki and Uusimaa.
The MIC values of ciproﬂoxacin (Bayer, Leverkusen, Ger-
many) were determined by an agar dilution method according
to the CLSI guidelines [17]. Mueller–Hinton agar (Oxoid, Bas-
ingstoke, UK) plates supplemented with deﬁbrinated sheep
blood (5%) were used. C. jejuni strain ATCC 33560 was
included as a control. The plates were incubated in a micro-
aerobic atmosphere at 36C for 48 h. The MIC was deﬁned
as the lowest concentration of ciproﬂoxacin that completely
inhibited visible growth. Isolates for which MICs of ‡4 mg/L
were determined were considered to be resistant [18].
Statistical analyses were performed with Graphpad Prism
version 4.03 (GraphPad Software, San Diego, CA, USA) and
SPSS version 15.0 (SPSS, Chicago, IL, USA). The chi-square
test, Fisher’s exact test and the Mantel–Haenszel test were
used for comparison of categorical variables. The Mann–Whit-
ney test was used for comparison of age and MIC distributions
between different groups. All tests were two-sided, and a
p-value <0.05 was considered to be statistically signiﬁcant.
Results
During the 6-month study period, 373 patients had stool
samples positive for C. jejuni or C. coli. The questionnaire was
sent to 363 (97%) patients. The ten patients to whom no
questionnaires were sent included four patients whose physi-
cians could not be reached, three whose isolates were not
stored for analysis, two temporary foreign visitors, and one
patient co-infected with Salmonella typhi. In total, 206 of the
363 patients (57%) returned an adequate response to the
questionnaire. The MIC values for eight of the 206 Campylo-
bacter isolates could not be determined, because the isolates
were lost, and six further patients were excluded because of
co-infection (with Salmonella spp., Vibrio cholerae or Y. entero-
colitica); thus, 192 of the 363 patients (53%) were included in
the ﬁnal analysis. The median delay in responding to the
questionnaire after giving the stool sample was 22 days
(range, 8–99 days). Almost half (46%) of the included cases
were diagnosed during the seasonal peak of July and August.
Patient characteristics are summarized in Table 1. One
hundred and forty-eight patients (77%) had been abroad
within 2 weeks prior to the onset of symptoms. The most
frequently visited countries were Spain (21 patients), Bulgaria
(21 patients), India (13 patients), Turkey (11 patients) and
Thailand (ten patients). More than half of the patients who
had been abroad had visited one of these ﬁve countries. The
median age of patients who had been abroad within 2 weeks
prior to the onset of symptoms was 37 years, and the med-
ian age of the 44 patients who had not been abroad was
46 years (p 0.03; Mann–Whitney test).
All but one of the 192 patients included in the analysis
reported having had diarrhoea, and 160 patients reported
TABLE 1. Characteristics of the 192 Campylobacter-positive
patients included in the ﬁnal analysis
Characteristics
Included patients All patients
Infection acquired
S (N = 192)In Finland Abroad (% of N = 363)
Gender
Female 23 (52%) 88 (59%) 111 (58%) 52%
Male 21 (48%) 60 (41%) 81 (42%) 48%
Age (years)
0–9 4 (9%) 4 (3%) 8 (4%) 6%
10–19 0 12 (8%) 12 (6%) 9%
20–29 6 (14%) 35 (24%) 41 (21%) 25%
30–39 7 (16%) 31 (21%) 38 (20%) 18%
40–49 9 (20%) 28 (19%) 37 (19%) 17%
50–59 10 (23%) 20 (14%) 30 (16%) 13%
60 and
older
8 (18%) 18 (12%) 26 (14%) 10%
Median age
(years)
46 37 39 35
Antimicrobial treatment
Yes 34 (77%) 106 (72%) 140 (73%)
No 10 (23%) 41 (28%) 51 (27%)
Uncertain 1 1
For comparison, the age and gender distribution of the patients to whom the
questionnaires were originally sent is also shown.
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having had fever. Characteristics indicating a more severe
disease were reported by the patients as follows: 48 of 179
(27%) reported vomiting, 47 of 186 (25%) had had diarrhoea
for at least 10 days, 24 of 133 (18%) reported having had
bloody stools, and 31 of 189 (16%) reported having received
treatment at a hospital ward for at least 2 days. The propor-
tion of patients with no underlying disease did not signiﬁ-
cantly differ between those treated at hospital for at least
2 days (20 of 29; 69%) and those treated at hospital for
<2 days or not at all (122 of 155; 79%) (p 0.25; chi-square
test). No signiﬁcant difference in the prevalence of any
underlying disease was observed between domestically
infected patients (13 of 44; 30%) and those presumably
infected abroad (30 of 143; 21%) (p 0.24; chi-square test).
The prevalence of underlying diseases did not signiﬁcantly
differ between those with severe symptoms (bloody stools,
vomiting or diarrhoea lasting ‡10 days) and those who
reported no such symptoms.
A large number of patients were treated with antimicrobi-
als; 106 of 148 (72%) of patients presumably infected abroad
and 34 of 44 (77%) of domestically infected patients had
received antimicrobial drugs (Table 1). Macrolides (54%) and
ﬂuoroquinolones (49%) were the most commonly prescribed
antimicrobial drugs. Multiple antimicrobials were prescribed
for 19% of the patients. Among the patients with ciproﬂoxa-
cin-susceptible isolates, 69 of 95 (73%) were treated with an-
timicrobials, whereas the ﬁgure for those infected with
ciproﬂoxacin-resistant isolates was 71 of 97 (73%). Among
those patients who reported having had bloody stools, 19 of
24 (79%) had been treated with antimicrobials, as compared
to 77 of 109 (71%) of those who reported no blood in
stools (p 0.46; Fisher’s exact test).
The distribution of MIC values for ciproﬂoxacin for all
192 Campylobacter isolates is shown in Fig. 1. All domestic
isolates except one were susceptible to ciproﬂoxacin,
whereas isolates presumably obtained abroad were fre-
quently resistant.
C. coli was isolated from 26 of 192 (14%) patients. Infec-
tion with C. coli was not associated with more severe symp-
toms or longer duration of illness than infection with
C. jejuni. The proportion of isolates resistant to ciproﬂoxacin
was 13 of 26 (50%) for C. coli isolates, as compared to 84 of
166 (51%) for C. jejuni isolates.
Bloody stools were signiﬁcantly more often reported by
patients with diarrhoea lasting 10 days or more (p 0.03; chi-
square test) and by those who had not travelled abroad
within 2 weeks prior to becoming ill (p 0.01; chi-square test).
When analysed separately according to different age groups,
bloody stools were associated with domestic infections only
within the age group of 30–59 years (p 0.01; Mantel–Haens-
zel test), whereas an association between bloody stools and
longer duration of diarrhoea was only observed in the youn-
gest age group, 0–29 years (p 0.02; Mantel–Haenszel test). In
the oldest-age group, 60–89 years, nobody reported having
had bloody stools.
Of all the 192 Campylobacter isolates included, 97 (51%)
were resistant to ciproﬂoxacin (MIC: ‡4 mg/L), whereas
among the Campylobacter isolates causing bloody diarrhoea,
16 (67%) were highly susceptible to ciproﬂoxacin (MIC:
0.06–0.25 mg/L), as shown in Fig. 2. The distribution of cip-
roﬂoxacin MICs of the isolates differed signiﬁcantly
between the patients who reported bloody stools and
those who did not (p 0.04; Mann–Whitney test). Hospital-
ization was not associated with any particular symptom or
duration of symptoms. Among the patients treated at hos-
pital for 2 days or more, 20 (65%) had ciproﬂoxacin-sus-
ceptible isolates. The distribution of ciproﬂoxacin MICs for
the isolates from patients who received hospital treatment
for at least 2 days was signiﬁcantly different from the
respective distribution for patients who had been treated
at hospital for <2 days or not at all (p 0.01; Mann–Whit-
ney test).
Discussion
Ciproﬂoxacin-resistant C. jejuni and C. coli isolates were not
associated with severe disease, i.e. disease with bloody stools
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FIG. 1. The distribution of ciproﬂoxacin MICs
for 192 Campylobacter jejuni and Campylobacter
coli isolates. MIC values are shown separately
for isolates acquired domestically and abroad.
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or diarrhoea lasting for ‡10 days or leading to hospital treat-
ment.
Instead, highly ciproﬂoxacin-susceptible isolates seemed to
cause a more invasive disease, as characterized by bloody
stools, and reﬂected in a higher number of patients reporting
hospitalization.
This study showed that ‘domestic’ Campylobacter isolates
in Finland are still almost exclusively susceptible to ciproﬂox-
acin, as only one of the isolates (2%) from the patients con-
sidered to have acquired infection domestically was resistant
to ciproﬂoxacin. Bloody stools were signiﬁcantly associated
with domestically acquired infections within the age group of
30–59 years. This particular age group included a total of
105 patients (26 patients with domestically acquired infec-
tions and 79 with infections probably acquired abroad).
None of the patients in the oldest age group reported
bloody stools. In a Swedish study that provided no suscepti-
bility data, a higher mortality rate was observed among
patients with domestically acquired Campylobacter infections,
which was speculated to be due to better health conditions
of those who had been able to travel [19]. In the present
study, patients with domestically acquired infections, although
older in general, did not have underlying diseases signiﬁcantly
more often than those who had travelled abroad prior to
becoming ill. Furthermore, bloody stools were only reported
by young and middle-aged persons. Thus, neither older age
nor impaired general health conditions explain the more
unfavourable outcome of the domestically obtained infections
characterized by bloody stools. This ﬁnding indicates either
that domestic infections have a tendency to be more severe,
or that the patients with a severe disease and infected in Fin-
land may have been more active in answering and returning
the questionnaires, compared to others.
The results of studies on whether resistance to ﬂuoroqui-
nolones increases the severity of Campylobacter infections
have been taken to support and to reject that hypothesis. In
an English study with a large number of patients, no differ-
ences in hospital admission or mean length of illness were
observed when patients with ciproﬂoxacin-susceptible iso-
lates and patients with resistant isolates were compared
[11]. However, Nelson et al. [12] reported that persons with
ciproﬂoxacin-resistant Campylobacter isolates had longer-last-
ing diarrhoea. In two separate Danish studies, quinolone
resistance was associated with a longer duration of disease
[13], and a greater risk of adverse events [14]. In contrast,
in a recent re-analysis by Wassenaar et al. [16], no
association between ﬂuoroquinolone-resistant Campylobacter
isolates and prolonged duration of diarrhoea could be
observed. The current study supports the results of the
re-analysis, and suggests that infections of domestic origin
may actually cause a more severe disease, e.g. with bloody
diarrhoea, which, on the other hand, is mostly attributed to
isolates highly susceptible to ciproﬂoxacin.
The majority of the patients infected in Finland and of the
patients presumably infected abroad were treated with anti-
microbials. However, the impact of the administration of
antibiotics on the course of the disease could not be analy-
sed, because of scarce information on the timing and length
of treatments. Although patients with infections caused by
domestic ciproﬂoxacin-susceptible strains, and those with
infections caused by highly ciproﬂoxacin-susceptible strains in
general, were more likely to have been treated with effective
antimicrobials, the disease in these cases was actually more
severe, as concluded from more frequently reported bloody
stools.
This ﬁnding is consistent with the conclusion of a previous
meta-analysis that the overall effect of antimicrobial treat-
ment on Campylobacter infection was only marginal [6]. The
effect of antidiarrhoeal medication on the severity of symp-
toms was not considered in the present study. However, it
would have been difﬁcult to analyse the independent impact
of antidiarrhoeal medicines on the outcome of the disease,
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FIG. 2. The distribution of ciproﬂoxacin MICs
for Campylobacter isolates from 24 patients
reporting bloody stools and 109 patients who
did not report bloody stools.
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because the majority of the patients had been treated with
antimicrobials.
The present study is based on information reported by
the patients themselves, which has both advantages and limi-
tations. The patients were able to describe the symptoms,
treatment and other aspects of their illness in detail, and the
information was easily interpreted and linked to the corre-
sponding Campylobacter isolates. Only one case was excluded
from this study due to a questionnaire that could not be
interpreted, indicating that the questions were rather easy to
understand. However, probably not all patients were
reached, and reminders were not possible, because the infor-
mation had to be sent to the patients’ physicians ﬁrst. Fur-
thermore, some of the returned questionnaires were only
partly answered. The patient cohort may, however, be
regarded as quite representative, because over 50% of all
patients diagnosed at the Helsinki University Central Hospital
Laboratory as Campylobacter-positive during the 6-month
period participated.
In conclusion, ciproﬂoxacin-susceptible isolates showed a
tendency to cause bloody stools and lead to hospital treatment
more often than ciproﬂoxacin-resistant isolates. This suggests
that ciproﬂoxacin-susceptible isolates may be associated with
a less favourable outcome of Campylobacter infection.
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